Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Jan 02, 2023
ENHERTU is an antibody-drug conjugate composed of an anti-HER2 antibody and a cytotoxic topoisomerase I inhibitor. Three components make up this ADC: A topoisomerase inhibitor that is covalently linked to, Humanized anti-HER2 IgG1 monoclonal antibody (mAb) via, Tetrapeptide-based cleavable linker Rec...
Read More...
Jan 11, 2019
Breast cancer develops when breast tissue cells grow abnormally and multiply. In essence, the hormones-- estrogen and progesterone-- and excess levels of human epidermal growth factor receptor 2 (HER2) protein are the known drivers of breast cancer. By testing samples of breast cancer tissue for hormone receptors a...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper